Global Artificial Intelligence (AI) in Epidemiology Market Forecast 2024-2032

The global artificial intelligence (AI) in epidemiology market is forecasted to generate a CAGR of 27.33% over the projection years of 2024-2032. Key drivers facilitating the market's growth include the early detection and surveillance of disease outbreaks, the growing need for predictive modeling to forecast disease trends, and data availability for epidemiological research.

MARKET INSIGHTS

Early detection and surveillance of disease outbreaks play a pivotal role in driving the growth of the global artificial intelligence (AI) in epidemiology market. By leveraging AI-powered algorithms on vast datasets, public health authorities can swiftly identify emerging threats, enabling timely interventions to mitigate the spread of infectious diseases. This proactive approach not only saves lives but also reduces healthcare costs associated with treating widespread outbreaks.

Furthermore, the adoption of AI in epidemiology enhances the efficiency and accuracy of disease surveillance systems, enabling real-time monitoring of population health trends. This capability enables healthcare stakeholders to anticipate potential outbreaks, allocate resources effectively, and implement targeted interventions, thereby minimizing the impact of epidemics on public health and economies.

The increasing integration of AI technologies into epidemiological research and public health infrastructure fosters collaborations between governments, research institutions, and industry players. These partnerships drive innovation in AI algorithms and data analytics, leading to the development of more sophisticated tools for disease detection, prediction, and response. Consequently, the demand for AI solutions in epidemiology continues to surge, fueling the growth of the global market as stakeholders recognize the critical role of early detection and surveillance in safeguarding public health.

REGIONAL INSIGHTS

The global artificial intelligence (AI) in epidemiology market growth examination compiles the geographical study of Europe, Asia-Pacific, North America, and Rest of World. North America is set to be a major region in the global market during the forecast period.

North America boasts a sophisticated healthcare infrastructure with advanced tools like electronic health records (EHRs) and strong data systems, enabling seamless integration and use of AI solutions. The Government Accountability Office (GAO) and the National Academy of Medicine (NAM) are collaborating on an initiative to explore AI/ML applications in healthcare, assessing their impact and identifying key strategies for optimizing their use. This effort significantly accelerates progress in the North America AI in epidemiology market.

COMPETITIVE INSIGHTS

In the competitive landscape of AI in epidemiology, companies are vying to offer innovative solutions leveraging advanced algorithms and data analytics to enhance disease surveillance and prediction. Key players are focused on developing robust AI models that can efficiently analyze vast amounts of healthcare data to provide actionable insights for public health agencies and healthcare providers.

Additionally, partnerships with research institutions and government bodies are crucial for staying ahead in this rapidly evolving market. Additionally, some of the top companies in the global market are Epic Systems Corporation, Microsoft Corporation, Meditech, etc.

Our report offerings include:

Explore key findings of the overall market
Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
Market Segmentation caters to a thorough assessment of key segments with their market estimations
Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
Key analytics: Porter's Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments

Product Code: 82541

1. RESEARCH SCOPE & METHODOLOGY

1.1. STUDY OBJECTIVES
1.2. METHODOLOGY
1.3. ASSUMPTIONS & LIMITATIONS

2. EXECUTIVE SUMMARY

2.1. MARKET SIZE & ESTIMATES
2.2. MARKET OVERVIEW
2.3. SCOPE OF STUDY
2.4. CRISIS SCENARIO ANALYSIS
- 2.4.1. IMPACT OF COVID-19 ON ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET
2.5. MAJOR MARKET FINDINGS
- 2.5.1. PUBLIC-PRIVATE PARTNERSHIP IN AI FOR HEALTH INFECTION PREDICTION & FORECASTING
- 2.5.2. RISING APPLICATIONS OF AI IN PERSONALIZED MEDICATIONS
- 2.5.3. INCREASING POPULARITY IN INFECTION PREDICTION AND FORECASTING ON CLOUD-BASED PLATFORMS

3. MARKET DYNAMICS

3.1. KEY DRIVERS
- 3.1.1. EARLY DETECTION AND SURVEILLANCE OF DISEASE OUTBREAKS
- 3.1.2. PREDICTIVE MODELING TO FORECAST DISEASE TRENDS
- 3.1.3. DATA AVAILABILITY FOR EPIDEMIOLOGICAL RESEARCH
3.2. KEY RESTRAINTS
- 3.2.1. PRIVACY AND ETHICAL CONCERNS REGARDING SENSITIVE PATIENT DATA
- 3.2.2. DATA QUALITY AND AVAILABILITY CHALLENGES

4. KEY ANALYTICS

4.1. KEY MARKET TRENDS
- 4.1.1. ADVANCEMENTS IN MACHINE LEARNING AND DATA ANALYTICS
- 4.1.2. EXPANSION OF TELEHEALTH AND REMOTE MONITORING
- 4.1.3. INTEGRATION OF AI IN PUBLIC HEALTH SYSTEMS
4.2. PORTER'S FIVE FORCES ANALYSIS
- 4.2.1. BUYERS POWER
- 4.2.2. SUPPLIERS POWER
- 4.2.3. SUBSTITUTES
- 4.2.4. NEW ENTRANTS
- 4.2.5. INDUSTRY RIVALRY
4.3. GROWTH PROSPECT MAPPING
4.4. MARKET MATURITY ANALYSIS
4.5. MARKET CONCENTRATION ANALYSIS

5. MARKET BY DEPLOYMENT

5.1. ON-PREMISE
- 5.1.1. MARKET FORECAST FIGURE
- 5.1.2. SEGMENT ANALYSIS
5.2. WEB-BASED
- 5.2.1. MARKET FORECAST FIGURE
- 5.2.2. SEGMENT ANALYSIS
5.3. CLOUD-BASED
- 5.3.1. MARKET FORECAST FIGURE
- 5.3.2. SEGMENT ANALYSIS

6. MARKET BY APPLICATION

6.1. INFECTION PREDICTION & FORECASTING
- 6.1.1. MARKET FORECAST FIGURE
- 6.1.2. SEGMENT ANALYSIS
6.2. DISEASE & SYNDROMIC SURVEILLANCE
- 6.2.1. MARKET FORECAST FIGURE
- 6.2.2. SEGMENT ANALYSIS
6.3. MONITORING POPULATION HEALTH & INCIDENCE/ PREVALENCE
- 6.3.1. MARKET FORECAST FIGURE
- 6.3.2. SEGMENT ANALYSIS

7. MARKET BY END USE

7.1. GOVERNMENT & STATE AGENCIES
- 7.1.1. MARKET FORECAST FIGURE
- 7.1.2. SEGMENT ANALYSIS
7.2. RESEARCH LABS
- 7.2.1. MARKET FORECAST FIGURE
- 7.2.2. SEGMENT ANALYSIS
7.3. PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
- 7.3.1. MARKET FORECAST FIGURE
- 7.3.2. SEGMENT ANALYSIS
7.4. HEALTHCARE PROVIDERS
- 7.4.1. MARKET FORECAST FIGURE
- 7.4.2. SEGMENT ANALYSIS

8. GEOGRAPHICAL ANALYSIS

8.1. NORTH AMERICA
- 8.1.1. MARKET SIZE & ESTIMATES
- 8.1.2. NORTH AMERICA ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET DRIVERS
- 8.1.3. NORTH AMERICA ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET CHALLENGES
- 8.1.4. KEY PLAYERS IN NORTH AMERICA ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET
- 8.1.5. COUNTRY ANALYSIS
  - 8.1.5.1. UNITED STATES
  - 8.1.5.1.1. UNITED STATES ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET SIZE & OPPORTUNITIES
  - 8.1.5.2. CANADA
  - 8.1.5.2.1. CANADA ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET SIZE & OPPORTUNITIES
8.2. EUROPE
- 8.2.1. MARKET SIZE & ESTIMATES
- 8.2.2. EUROPE ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET DRIVERS
- 8.2.3. EUROPE ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET CHALLENGES
- 8.2.4. KEY PLAYERS IN EUROPE ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET
- 8.2.5. COUNTRY ANALYSIS
  - 8.2.5.1. UNITED KINGDOM
  - 8.2.5.1.1. UNITED KINGDOM ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET SIZE & OPPORTUNITIES
  - 8.2.5.2. GERMANY
  - 8.2.5.2.1. GERMANY ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET SIZE & OPPORTUNITIES
  - 8.2.5.3. FRANCE
  - 8.2.5.3.1. FRANCE ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET SIZE & OPPORTUNITIES
  - 8.2.5.4. ITALY
  - 8.2.5.4.1. ITALY ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET SIZE & OPPORTUNITIES
  - 8.2.5.5. SPAIN
  - 8.2.5.5.1. SPAIN ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET SIZE & OPPORTUNITIES
  - 8.2.5.6. REST OF EUROPE
  - 8.2.5.6.1. REST OF EUROPE ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET SIZE & OPPORTUNITIES
8.3. ASIA-PACIFIC
- 8.3.1. MARKET SIZE & ESTIMATES
- 8.3.2. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET DRIVERS
- 8.3.3. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET CHALLENGES
- 8.3.4. KEY PLAYERS IN ASIA-PACIFIC ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET
- 8.3.5. COUNTRY ANALYSIS
  - 8.3.5.1. CHINA
  - 8.3.5.1.1. CHINA ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET SIZE & OPPORTUNITIES
  - 8.3.5.2. JAPAN
  - 8.3.5.2.1. JAPAN ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET SIZE & OPPORTUNITIES
  - 8.3.5.3. INDIA
  - 8.3.5.3.1. INDIA ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET SIZE & OPPORTUNITIES
  - 8.3.5.4. SOUTH KOREA
  - 8.3.5.4.1. SOUTH KOREA ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET SIZE & OPPORTUNITIES
  - 8.3.5.5. AUSTRALIA & NEW ZEALAND
  - 8.3.5.5.1. AUSTRALIA & NEW ZEALAND ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET SIZE & OPPORTUNITIES
  - 8.3.5.6. REST OF ASIA-PACIFIC
  - 8.3.5.6.1. REST OF ASIA-PACIFIC ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET SIZE & OPPORTUNITIES
8.4. REST OF WORLD
- 8.4.1. MARKET SIZE & ESTIMATES
- 8.4.2. REST OF WORLD ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET DRIVERS
- 8.4.3. REST OF WORLD ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET CHALLENGES
- 8.4.4. KEY PLAYERS IN REST OF WORLD ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET
- 8.4.5. REGIONAL ANALYSIS
  - 8.4.5.1. LATIN AMERICA
  - 8.4.5.1.1. LATIN AMERICA ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET SIZE & OPPORTUNITIES
  - 8.4.5.2. MIDDLE EAST & AFRICA
  - 8.4.5.2.1. MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET SIZE & OPPORTUNITIES

9. COMPETITIVE LANDSCAPE

9.1. KEY STRATEGIC DEVELOPMENTS
- 9.1.1. MERGERS & ACQUISITIONS
- 9.1.2. PRODUCT LAUNCHES & DEVELOPMENTS
- 9.1.3. PARTNERSHIPS & AGREEMENTS
- 9.1.4. BUSINESS EXPANSIONS & DIVESTITURES
9.2. COMPANY PROFILES
- 9.2.1. ALPHABET INC
  - 9.2.1.1. COMPANY OVERVIEW
  - 9.2.1.2. PRODUCT LIST
  - 9.2.1.3. STRENGTHS & CHALLENGES
- 9.2.2. BAYER HEALTHCARE
  - 9.2.2.1. COMPANY OVERVIEW
  - 9.2.2.2. PRODUCT LIST
  - 9.2.2.3. STRENGTHS & CHALLENGES
- 9.2.3. CARDIOLYSE
  - 9.2.3.1. COMPANY OVERVIEW
  - 9.2.3.2. PRODUCT LIST
  - 9.2.3.3. STRENGTHS & CHALLENGES
- 9.2.4. CERNER CORPORATION
  - 9.2.4.1. COMPANY OVERVIEW
  - 9.2.4.2. PRODUCT LIST
  - 9.2.4.3. STRENGTHS & CHALLENGES
- 9.2.5. COGNIZANT
  - 9.2.5.1. COMPANY OVERVIEW
  - 9.2.5.2. PRODUCT LIST
  - 9.2.5.3. STRENGTHS & CHALLENGES
- 9.2.6. ECLINICAL WORKS INC
  - 9.2.6.1. COMPANY OVERVIEW
  - 9.2.6.2. PRODUCT LIST
  - 9.2.6.3. STRENGTHS & CHALLENGES
- 9.2.7. EPIC SYSTEMS CORPORATION
  - 9.2.7.1. COMPANY OVERVIEW
  - 9.2.7.2. PRODUCT LIST
  - 9.2.7.3. STRENGTHS & CHALLENGES
- 9.2.8. INTEL CORPORATION
  - 9.2.8.1. COMPANY OVERVIEW
  - 9.2.8.2. PRODUCT LIST
  - 9.2.8.3. STRENGTHS & CHALLENGES
- 9.2.9. KOMODO HEALTH
  - 9.2.9.1. COMPANY OVERVIEW
  - 9.2.9.2. PRODUCT LIST
  - 9.2.9.3. STRENGTHS & CHALLENGES
- 9.2.10. MEDITECH
  - 9.2.10.1. COMPANY OVERVIEW
  - 9.2.10.2. PRODUCT LIST
  - 9.2.10.3. STRENGTHS & CHALLENGES
- 9.2.11. MICROSOFT CORPORATION
  - 9.2.11.1. COMPANY OVERVIEW
  - 9.2.11.2. PRODUCT LIST
  - 9.2.11.3. STRENGTHS & CHALLENGES
- 9.2.12. PREDIXION HEALTHCARE (JVION LLC)
  - 9.2.12.1. COMPANY OVERVIEW
  - 9.2.12.2. PRODUCT LIST
  - 9.2.12.3. STRENGTHS & CHALLENGES
- 9.2.13. SAS INSTITUTE
  - 9.2.13.1. COMPANY OVERVIEW
  - 9.2.13.2. PRODUCT LIST
  - 9.2.13.3. STRENGTHS & CHALLENGES
- 9.2.14. SIEMENS HEALTHINEERS
  - 9.2.14.1. COMPANY OVERVIEW
  - 9.2.14.2. PRODUCT LIST
  - 9.2.14.3. STRENGTHS & CHALLENGES